Bendamustine plus rituximab: is it a BRIGHT idea?

Affiliations

¹ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy. carlo.visco@univr.it.
² Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
³ Medical Direction, University Hospital of Verona, Verona, Italy.
⁴ Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.

Free article

Comment

Carlo Visco et al. Chin Clin Oncol. 2020 Apr.

Free article

. 2020 Apr;9(2):22.

doi: 10.21037/cco.2019.10.03. Epub 2019 Nov 6.

¹ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy. carlo.visco@univr.it.
² Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
³ Medical Direction, University Hospital of Verona, Verona, Italy.
⁴ Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.

No abstract available

Comment on

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Flinn IW, et al. Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3. Blood. 2014. PMID: 24591201 Free PMC article. Clinical Trial.